Success Metrics

Clinical Success Rate

22.2%

Based on 2 completed trials

Completion Rate

22%(2/9)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

7(70%)

Phase Distribution

Ph phase_1

30%

Ph phase_2

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

3(33.3%)

Phase 2Efficacy & side effects

6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

22.2%

2 of 9 finished

Non-Completion Rate

77.8%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(7)

Other(1)

Detailed Status

Terminated7

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

22.2%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (33.3%)

Phase 26 (66.7%)

Trials by Status

unknown110%

completed220%

terminated770%

Recent Activity

0 active trials

Showing 5 of 10

unknown

Clinical Trials (10)

Showing 10 of 10 trials

NCT01945164

XL999 Administered Intravenously to a Subject With Advanced Malignancies

Unknown

NCT00955084Phase 1

Maintenance Study on the Long Term Safety of XL999

Completed

NCT00304590Phase 2

Study of XL999 in Patients With Multiple Myeloma

Terminated

NCT00277303Phase 2

Study of XL999 in Patients With Metastatic Colorectal Cancer

Terminated

NCT00277290Phase 2

Study of XL999 in Patients With Previously Treated Ovarian Cancer

Terminated

NCT00322673Phase 2

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

Terminated

NCT00277329Phase 2

Study of XL999 in Patients With Non-small Cell Lung Cancer

Terminated

NCT00491699Phase 1

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Terminated

NCT00104117Phase 1

Study of XL999 in Adults With Solid Tumors

Completed

NCT00277316Phase 2

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Terminated

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10